| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.035 | 0.5 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.5 |
| mRNA | GSK1120212 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.019 | 0.5 |